What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma

Addressing Current Questions and Controversies in the Management of Multiple MyelomaПодробнее

Multiple Myeloma | What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of M...Подробнее

Relapsed Refractory Multiple Myeloma | Current Treatment Options | Options on the HorizonПодробнее

Overview of the CD38 antibody in multiple myelomaПодробнее

CD38 Antibodies in Multiple Myeloma: What Next?Подробнее

CD38: a promising target for multiple myeloma antibody therapyПодробнее

Optimising the management of multiple myeloma in the early relapsed/refractory settingПодробнее

Mechanisms of action of CD38 antibodies in myelomaПодробнее

The importance of anti-CD38 monoclonal antibodies for multiple myelomaПодробнее

Reaching the Next Level of Myeloma Patient Care: Antibody Therapy and Novel Mechanisms of ActionПодробнее

Safety Profile of Anti-CD38 Monoclonal Antibodies in MMПодробнее

CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079Подробнее

Alfred Garfall, MD and Bea Razzo, MD on Bispecific Antibodies in Multiple MyelomaПодробнее

Future Direction of CD38 Antibodies in Multiple MyelomaПодробнее

Stem cell collection in patients with multiple myeloma treated with anti-CD38 monoclonal antibodiesПодробнее

Anti-CD38 immunotherapy treatment for multiple myelomaПодробнее

Clinical management of myeloma: vaccination, novel therapeutic agents and more at COMy 2022Подробнее

BCMA-Directed Therapy in Multiple Myeloma: Assessing the Clinical ImpactПодробнее

MYELOMA UNIVERSITY | Monoclonal Antibodies as Treatment for Multiple MyelomaПодробнее

Dual-targeting of Slamf-7 and CD38 with elotuzumab and isatuximab in multiple myelomaПодробнее

Immunotherapy in myeloma: current strategies and future perspectivesПодробнее

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myelomaПодробнее